Literature DB >> 10372541

HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations.

A Spurkland1, S Saarinen, K M Boberg, S Mitchell, U Broome, L Caballeria, E Ciusani, R Chapman, G Ercilla, O Fausa, I Knutsen, A Pares, F Rosina, O Olerup, E Thorsby, E Schrumpf.   

Abstract

The association of primary sclerosing cholangitis (PSC) to HLA class II genes was studied by comparing patients from five different European populations. Deduced HLA-DRB1, DQA1, DQB1 haplotypes of 256 PSC patients from England, Italy, Norway, Spain and Sweden were compared to those observed in 764 ethnically-matched controls. Increased frequencies of the DRB1*03, DQA1*0501, DQB1*02 (RR=3.0, P<0.00001) and the DRB1*13, DQA1*0103, DQB1*0603 haplotypes (RR=2.4, P<0.0001) were observed in all five patient groups. A total of 16% of the PSC patients were homozygous for the DRB1*03, DQA1*0501, DQB1*02 haplotype compared to 1% of the controls (RR=20, P<0.0001). The DRB1*04, DQA1*03, DQB1*0302 haplotype was significantly reduced in frequency(RR=0.4, P<0.00001). Among Norwegian, Swedish and British patients that did not carry neither the DRB1*03, DQA1*0501, DQB1*02 nor the DRB1*13, DQA1*0103, DQB1*0603 haplotype, an increased frequency of the DRB1*15, DQA1*0102, DQB1*0602 haplotype was observed (RR=2.0, P<0.0001). Thus, PSC was found to be positively associated to three different HLA class II haplotypes (i.e. the DRB1*03, DQA1*0501, DQB1*02, the DRB1*15, DQA1*0102, DQB1*0602 and the DRB1*13, DQA1*0103, DQB1*0603 haplotypes) and negatively associated to one HLA class II haplotype (i.e. the DRB1*04, DQB1*0302 haplotype).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372541     DOI: 10.1034/j.1399-0039.1999.530502.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  41 in total

1.  Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism.

Authors:  P L Bittencourt; S A Palacios; E L R Cançado; F J Carrilho; G Porta; J Kalil; A C Goldberg
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 2.  Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature.

Authors:  Abdullah M S Al-Osaimi; Carl L Berg
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

3.  Review.

Authors:  Christopher B O'Brien
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

4.  Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations.

Authors:  Christopher L Bowlus; Chin-Shang Li; Tom H Karlsen; Benedicte A Lie; Carlo Selmi
Journal:  Liver Transpl       Date:  2010-11       Impact factor: 5.799

5.  DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population.

Authors:  C L Noble; E R Nimmo; H Drummond; L Smith; I D R Arnott; J Satsangi
Journal:  Gut       Date:  2005-04-20       Impact factor: 23.059

Review 6.  Immunopathogenesis of primary sclerosing cholangitis.

Authors:  Joy Worthington; Sue Cullen; Roger Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 7.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 8.  Sclerosing cholangitis epidemiology and etiology.

Authors:  Konstantinos N Lazaridis
Journal:  J Gastrointest Surg       Date:  2007-10-24       Impact factor: 3.452

Review 9.  Etiopathogenesis of primary sclerosing cholangitis.

Authors:  Roger Chapman; Sue Cullen
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

10.  Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.

Authors:  S A Mitchell; M Thyssen; T R Orchard; D P Jewell; K A Fleming; R W Chapman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.